glp-1 who should not take Why do patients stop drugs? GLP-1 Weight Loss Drugs: Impact
Description
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Whats Next for Compounded GLP-1 Drugs
Now I feel lighter and more energetic
GLP-1s are proving their value well beyond the scale, with benefits ranging from improved glycemic control and reduced cardiovascular risk to better mobility and quality of life
